TENX Tenax Therapeutics Inc.

1.34
-0.03  -2%
Previous Close 1.37
Open 1.35
Price To Book 1.38
Market Cap 9,034,092
Shares 6,741,860
Volume 29,338
Short Ratio
Av. Daily Volume 40,251
Stock charts supplied by TradingView

NewsSee all news

  1. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    24 patients have been randomized 86% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.6 mmHg during exercise following the initial

  2. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    15 patients have been randomized 83% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced , on average, by 8 mmHg during exercise following the initial

  3. Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

  4. Tenax Therapeutics Provides Clinical Development Update

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data due 1H 2020.
Levosimendan
Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)
Phase 2b trial did not meet primary endpoint.
Levosimendan
Septic shock
Phase 3 top line data released January 31, 2017 - primary endpoints not met. Met with FDA May 10, 2017 to discuss potential NDA submission.
Levosimendan
Reduce the incidence of low cardiac output syndrome during cardiac surgery

Latest News

  1. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    24 patients have been randomized 86% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced, on average, by 7.6 mmHg during exercise following the initial

  2. Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial

    15 patients have been randomized 83% initial response rate to qualify for randomization Pulmonary capillary wedge pressure (PCWP) was reduced , on average, by 8 mmHg during exercise following the initial

  3. Tenax Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,

  4. Tenax Therapeutics Provides Clinical Development Update

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,